The principal aim of this study was to establish whether a metabolic monitoring program implemented for second-generation antipsychotic medications (SGAs) was associated with any reduction in the prevalence of metabolic syndrome in adult inmates treated with antipsychotic medications in the New Jersey Department of Corrections. The average prevalence of metabolic syndrome in those prescribed SGAs decreased from 17.9% during the years before metabolic monitoring to 14.3% during the years of monitoring. The number of patients prescribed antipsychotic medication decreased a net 35% over 9 years of the study. We conclude that metabolic monitoring was one of the several administrative interventions over the study period that reduced the unnecessary exposure of inmates to the risks of antipsychotic medications.
AguilarM., BhuketT., TorresS., LiuB., WongR. J. (2015). Prevalence of the metabolic syndrome in the United States, 2003-2012. Journal of the American Medical Association, 313, 1973–1974.
2.
AlbertiK. G., EckelR. H., GrundyS. M., ZimmetP. Z., CleemanJ. I., DonatoK. A.…SmithS. C.Jr (2009). Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation, 120, 1640–1645.
3.
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Journal of Clinical Psychiatry, 65, 267–272.
4.
Antai-OtongD. (2004). Metabolic effects associated with atypical antipsychotic medications. Perspectives in Psychiatric Care, 40, 70–72.
5.
BatkiS. L., MeszarosZ. S., StrutynskiK., DimmockJ. A., LeontievaL., Ploutz-SnyderR.…DrayerR. A. (2009). Medical comorbidity in patients with schizophrenia and alcohol dependence. Schizophrenia Research, 107, 139–146.
6.
BinswangerI. A., KruegerP. M., SteinerJ. F. (2009). Prevalence of chronic medical conditions among jail and prison inmates in the USA compared with the general population. Journal of Epidemiology and Community Health, 63, 912–919.
CorrellC. U., LeuchtS., KaneJ. M. (2004). Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. American Journal of Psychiatry, 161, 414–425.
9.
CzoborP., VolavkaJ., SheitmanB., LindenmayerJ. P., CitromeL., McEvoyJ.…LiebermanJ. A. (2002). Antipsychotic-induced weight gain and therapeutic response: A differential association. Journal of Clinical Psychopharmacology, 22, 244–251.
10.
DickertJ., WilliamsJ. M., ReevesR., GaraM., DeBilioL. (2015). Decreased mortality rates of inmates with mental illness after a tobacco-free prison policy. Psychiatric Services. 66, 975–979.
11.
DrussB. G., ZhaoL., Von EsenweinS., MorratoE. H., MarcusS. C. (2011). Understanding excess mortality in persons with mental illness: 17-year follow up of a nationally representative U.S. survey. Medical Care, 49, 599–604.
12.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. (2001). Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Journal of the American Medical Association, 285, 2486–2497.
13.
FordE. S. (2005). Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: A summary of the evidence. Diabetes Care, 28, 1769–1778.
14.
GalassiA., ReynoldsK., HeJ. (2006). Metabolic syndrome and risk of cardiovascular disease: A meta-analysis. American Journal of Medicine, 119, 812–819.
15.
GamiA. S., WittB. J., HowardD. E., ErwinP. J., GamiL. A., SomersV. K., MontoriV. M. (2007). Metabolic syndrome and risk of incident cardiovascular events and death: A systematic review and meta-analysis of longitudinal studies. Journal of the American College of Cardiology, 49, 403–414.
16.
Hannan-JonesM., CapraS. (2016). Prevalence of diet-related risk factors for chronic disease in male prisoners in a high secure prison. European Journal of Clinical Nutrition, 70, 212–216. doi:10.1038/ejcn.2015.100
17.
HansenT., IngasonA., DjurovicS., MelleI., FengerM., GustafssonO.…WergeT. (2011). At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia. Biological Psychiatry, 70, 59–63.
18.
HassanL., SeniorJ., FrisherM., EdgeD., ShawJ. (2014). A comparison of psychotropic medication prescribing patterns in East of England prisons and the general population. Journal of Psychopharmacology, 28, 357–362.
19.
HauptD. W., FahnestockP. A., FlavinK. A., SchweigerJ. A., StevensA., HesslerM. J.…NewcomerJ. W. (2007). Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients. Neuropsychopharmacology, 32, 2561–2569.
20.
HoltR. G., PevelerR. C., ByrneC. D. (2004). Schizophrenia, the metabolic syndrome and diabetes. Diabetic Medicine, 21, 515–523.
21.
IsomaaB., AlmgrenP., TuomiT., ForsénB., LahtiK., NissénM.…GroopL. (2001). Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care, 24, 683–689.
22.
LaursenT. M., Munk-OlsenT., VestergaardM. (2012). Life expectancy and cardiovascular mortality in persons with schizophrenia. Current Opinion in Psychiatry, 25, 83–88.
23.
LiW., MaD., LiuM., LiuH., FengS., HaoZ.…ZhangS. (2008). Association between metabolic syndrome and risk of stroke: A meta-analysis of cohort studies. Cerebrovascular Diseases, 25, 539–547.
24.
LiebermanJ. A., StroupT. S., McEvoyJ. P., SwartzM. S., RosenheckR. A., PerkinsD. O.,…CATIE Investigators. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353, 1209–1223.
25.
McEvoyJ. P., MeyerJ. M., GoffD. C., NasrallahH. A., DavisS. M., SullivanL.…LiebermanJ. A. (2005). Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research, 80, 19–32.
26.
MorratoE. H., DrussB., HartungD. M., ValuckR. J., AllenR., CampagnaE., NewcomerJ. W. (2010). Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Archives of General Psychiatry, 67, 17–24.
27.
MottilloS., FilionK. B., GenestJ., JosephL., PiloteL., PoirierP.…EisenbergM. J. (2010). The metabolic syndrome and cardiovascular risk in a systematic review and meta-analysis. Journal of the American College of Cardiology, 56, 1113–1132.
28.
MozumdarA., LiguoriG. (2011). Persistent prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999-2006. Diabetes Care, 34, 216–219.
NewcomerJ. W. (2007). Metabolic considerations in the use of antipsychotic medications: A review of recent evidence. Journal of Clinical Psychiatry, 68, 20–27.
33.
PapanastasiouE. (2012). Interventions for the metabolic syndrome in schizophrenia: A review. Therapeutic Advances in Endocrinology and Metabolism, 3, 141–162.
34.
ReevesR. (2012). Guideline, education, and peer comparison reduce prescriptions of benzodiazepines and low-dose quetiapine in prison. Journal of Correctional Health Care, 18, 45–52.
35.
ReevesR., KaldanyH., LiebermanJ., VyasR. (2009). Creation of a metabolic monitoring program for second-generation (atypical) antipsychotics. Journal of Correctional Health Care, 15, 292–301.
36.
RojoL. E., GasparP. A., SilvaH., RiscoL., ArenaP., Cubillos-RoblesK., JaraB. (2015). Metabolic syndrome and obesity among users of second generation antipsychotics: A global challenge for modern psychopharmacology. Pharmacological Research, 101, 74–85.
37.
SahaS., ChantD., McGrathJ. (2007). A systematic review of mortality in schizophrenia: Is the differential mortality gap worsening over time?. Archives of General Psychiatry, 64, 1123–1131.
38.
SowellM., MukhopadhyayN., CavazzoniP., CarlsonC., MudaliarS., ChinnapongseS.…DananbergJ. (2003). Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: A prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. Journal of Clinical Endocrinology and Metabolism, 88, 5875–5880.
39.
TamburelloA., LiebermanJ., BaumR., ReevesR. (2012). Successful removal of quetiapine from a correctional formulary. Journal of the American Academy of Psychiatry and the Law, 40, 502–508.
40.
TiihonenJ., LönnqvistJ., WahlbeckK., KlaukkaT., NiskanenL., TanskanenA., HaukkaJ. (2009). 11-year follow-up of mortality in patients with schizophrenia: A population-based cohort study. Lancet, 374, 620–627.
41.
VidarsdottirS., de Leeuw van WeenenJ. E., FrölichM., RoelfsemaF., RomijnJ. A., PijlH. (2010). Effects of olanzapine and haloperidol on the metabolic status of healthy men. Journal of Clinical Endocrinology and Metabolism, 95, 118–125.
42.
WeidenP. J., McEvoyJ. P. (2005). Medical risk factors in patients with serious psychiatric disorders. Clinical Psychiatry News, 3, 1–4.
WormS. W., LundgrenJ. D. (2011). The metabolic syndrome in HIV. Best Practice and Research: Clinical Endocrinology & Metabolism, 25, 479–486.
45.
YoungS. L., TaylorM., LawrieS. M. (2015). “First do no harm.” A systematic review of the prevalence and management of antipsychotic adverse effects. Journal of Psychopharmacology, 29, 353–362.
